For UK Healthcare Professionals Only

It is estimated that:

  • 98%

    of patients who receive radiotherapy for head and neck cancer will develop some form of mucositis, which can include oral mucositis1

  • 40%

    of patients receiving chemotherapy will develop some degree of mucositis1

  • Protects the healthy rectal mucosa
  • Aids symptom relief and treatment of proctitis (rectal mucositis)
  • Aids the healing process

Mucosamin® Rectal Gel

Aids the symptom relief and treatment of proctitis (rectal mucositis)

Mucosamin® Rectal Gel supports the healing process of the damaged rectal mucosa and helps to treat the painful symptoms of rectal mucositis, caused by radiotherapy and/or chemotherapy of pelvic tumours. In the treatment of rectal mucositis, Mucosamin® helps to improves mucosa tropism, and is designed to prevent the onset of rectal mucositis and also avoid recurrence. Mucosamin is a medical device made up of sodium hyaluronate and four synthetic amino acids (glycine, L-proline, L-leucine and L-lysine).


6 x micro enemas, with 7g of gel

How to use

The Micro-enema can be used to ensure the entire affected areas can be reached

How often to use

Once or several times a day depending on the extent of symptoms

Legal category

CE Class IIb Medical Device

NHS List Price4





PIP Code

What is radiation proctitis?2

Radiation proctitis is a radiation induced rectal mucositis and is defined as an inflammatory process of the rectal mucosa that can occur almost immediately or up to 3 months after the initiation of radiotherapy. Symptoms of acute radiation proctitis include burning pain sensations, diarrhoea, nausea, cramps, tenesmus, urgency, mucous discharge, and minor bleeding.



Mucosamin Rectal Gel Clinical Summary3

193 patients undergoing radiation treatment for prostate carcinoma were randomised to prophylactic treatment with Mucosamin® rectal gel (n = 100) or control with non-topical steroid therapy (n=93) for prevention/treatment of actinic proctitis.

Treatment protocol
Mucosamin® was applied in the evening from the first day of treatment, up until two weeks after cessation of treatment as per the device instructions. All patients had weekly check-ups during the period and had a final follow-up 3 weeks after cessation of treatment. Four patients died during the study as a result of disease progression or cardiovascular events.

Considering an average follow-up of 24 months, the treatment group experienced significantly fewer G1 and G2 toxicities (p<0.05) compared with the control group and more G0 rectal toxicities were experienced in the treatment group (85 vs 71).

Compared with oral steroidal treatment, Mucosamin® was significantly more effective and reduced the number of incidences of actinic proctitis (inflammation of the lining of the rectum).




  • Reference 1.
    Available from: [Accessed October 2020]
  • Reference 2.
    Do, N. L. et al. Radiation proctitis: Current strategies in management. Gastroeneterol Res Pract.
  • Reference 3.
    1010461597 v 1.0 May 2019 Data on File
  • Reference 4. (accessed October 2020)